Can TMS and Esketamine Work Together to Treat Depression?
Depression is one of the most prevalent and debilitating mental health conditions worldwide. And in addition, around 30% of people
February 20, 2025 No Comments
Category: Spravato
Read More »
FDA expands approval for Spravato® as the first and only monotherapy for adults with treatment-resistant depression
The FDA has approved Spravato® (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression (TRD), in addition
February 9, 2025 No Comments